• Myelin is the coating on the nerve cells (neurons) of the nervous system that allows messages to travel rapidly in our body. Myelin wrapped around the neurons also keeps neurons healthy. In multiple sclerosis, the immune system attacks myelin disrupting electrical signals and making neurons vulnerable to chronic damage. Remyelination is the strategy to recoat the nerves with new myelin. Myelin-making cells called oligodendrocytes (“oligos”) are described. The podcast reviews recent laboratory breakthroughs in screening for new treatments to turn on immature oligos to repair myelin. The exciting initial steps are presented regarding the transition from the laboratory research into clinical trials with multiple sclerosis patients.

    Barry Singer, MD, Director of The MS Center for Innovations in Care at Missouri Baptist Medical Center interviews:

    Ari J Green, MD, Chief of Division of Neuroinflammation and Glial Biology, Medical Director of Multiple Sclerosis and Neuroinflammation Center, Debbie and Andy Rachleff Distinguished Professor of Neurology, Departments of Neurology and Ophthalmology, University of California San Francisco.

    To learn more, www..mslivingwell.org To share your MS story, check out www.ICanWithMS.org

  • Treatment approaches to multiple sclerosis continue to change. Over the past quarter of a century, MS went from an untreatable disease to a disease responsive to a broad array of oral, intravenous and self-injected medications. Greater long-term disease control is now possible for more people living with MS. However, undertreatment can result in significant physical disability including imbalance, weakness, visual loss, incontinence and pain and significant cognitive impairment including short-term memory loss, multitasking impairment and word-finding problems. This podcast outlines different treatment strategies to maximize quality of life long-term to realize your individual goals with the least disability. Information is presented on which people with MS might be at increased risk of disability and need early use of a highly effective medication. Treatment safety is weighed against the treatment benefits and risk of long-term disability.

    Barry Singer MD, Director of The MS Center for Innovations in Care, interviews two amazing MS specialists who are also phenomenal patient advocates:

    Heidi Crayton MD, Director of The MS Center of Greater Washington in the Virginia suburbs of Washington, DC. Dr. Crayton completed her neurology residency and multiple sclerosis fellowship at Georgetown University Hospital. She is a national leader in MS treatment and clinical trial investigator.

    Aaron Boster, MD, is an MS expert at Ohio Health in Columbus, Ohio. Dr. Boster completed his neurology residency at the University of Michigan in Ann Arbor and a fellowship focused on clinical neuroimmunology and multiple sclerosis at Wayne State University in Detroit. Dr. Boster continues to be active in clinical research, authoring academic publications and lecturing globally.

    To learn more about multiple sclerosis, go to: www.mslivingwell.org

    To share your MS story, check out: www.ICanWithMS.org

  • Missing episodes?

    Click here to refresh the feed.